Brainsway Ltd (BWAY)
NASDAQ:BWAY
Want to see BWAY full AI Analyst Report?
BWAY Stock Chart & Stats
$15.81
-$0.11(-1.13%)
At close: 4:00 PM EST
$15.81
-$0.11(-1.13%)
Day’s Range― - ―
52-Week Range$3.92 - $16.24
Previous CloseN/A
Volume9.67K
Average Volume (3M)185.96K
Market Cap
$648.99M
Enterprise Value$565.39M
Total Cash (Recent Filing)$67.95M
Total Debt (Recent Filing)$6.82M
Price to Earnings (P/E)14.8
Beta1.39
Next Earnings
May 13, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding40,033,028
10 Day Avg. Volume177,700
30 Day Avg. Volume185,964
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.48
Price to Sales (P/S)3.45
P/FCF Ratio11.06
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue10.81
Enterprise Value/Gross Profit14.33
Enterprise Value/Ebitda56.50
Forecast
1Y Price Target
$15.00Price Target Upside-5.12% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.18
Revenue Forecast (FY)$66.43M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Profitability TurnaroundSustained mid‑70s gross margins and a clear move to net profitability allow BrainsWay to fund growth from operations, support scalable margins as ARR expands, and reduce capital dependence. This margin base underpins durable operating leverage as multi‑year leases scale.
Recurring‑revenue Shift And Growing Installed BaseA shift to multi‑year system leases and an installed base >1,700 create predictable, annuity‑like cash flows and higher lifetime revenue per site. Recurring revenue increases visibility, supports utilization-driven consumable sales, and improves ROI on sales and clinical partnerships.
Regulatory & Payer Momentum With Supportive Clinical DataRobust peer‑reviewed SWIFT data plus recent clearance and payer moves reduce treatment burden and improve clinic throughput. Strong clinical evidence and easing reimbursement are structural enablers that can broaden adoption, shorten patient timelines, and expand TAM for non‑drug therapies.
Bears Say
Volatile Cash Flow GenerationAlthough FCF strengthened in 2024–2025, year‑over‑year declines and historically large swings indicate sensitivity to working capital and investment timing. This variability can stress reinvestment plans, M&A flexibility, and dividend/return policies during downturns.
Historic Profitability Volatility And Margin SensitivityThe firm only recently turned consistently profitable after years of losses; EBITDA margin erosion in 2025 highlights how reinvestment or utilization shifts can quickly compress earnings. This makes medium‑term cash generation and ROE less predictable if growth slows or costs rise.
Dependence On Clinician Adoption And ReimbursementLong‑term growth hinges on payer coverage and providers adopting Deep TMS. While recent insurer moves help, sustained expansion requires continued favorable coverage and provider training; adverse payer policy shifts or slow clinic uptake would materially constrain durable revenue growth.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was $3.92 and its highest was $16.24 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is $648.99M.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is May 13, 2026 which is in 24 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Mar 11, 2026. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.031 by $0.039.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Overvalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate is 0.03.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 40,033,028 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of $0.07 in its last earnings report, beating expectations of $0.031. Following the earnings report the stock price went up 8.34%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Brainsway Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (-5.12% Downside)
$15.00 (-5.12% Downside)
Blogger Sentiment
Bullish
BWAY Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 254.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
283.73%
12-Months-Change
Fundamentals
Return on Equity
12.01%
Trailing 12-Months
Asset Growth
19.72%
Trailing 12-Months
Company Description
Brainsway Ltd
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BWAY Company Deck
BWAY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
BrainsWay's Q3 2025 earnings call indicated strong growth and positive developments, including record revenue, increased system shipments, and successful strategic investments. Despite increased operating expenses and a delay in FDA clearance for Neurolief, the company's performance and raised guidance reflect a generally optimistic outlook.View all BWAY earnings summariesBWAY Stock 12 Month Forecast
Average Price Target
$15.00
▼(-5.12% Downside)
Technical Analysis
Sanuwave Health
―
Tactile Systems Technology
―
Viemed Healthcare
―
TriSalus Life Sciences
―
NeuroPace
―
Ownership Overview
―
Insiders
0.46% Mutual Funds
11.63% Other Institutional Investors
87.30% Public Companies and
Individual Investors